4. Legend Biotech Corporation (NASDAQ:LEGN)
Stock Upside: 78.73%
Market Capitalization: $6.24 billion
Legend Biotech Corporation (NASDAQ) ranks fourth among the most promising healthcare stocks according to Wall Street analysts, and Legend Biotech Corporation (NASDAQ) brings a high-risk, high-science cell therapy story to this healthcare stock ranking. Trading at $27.93, with Legend Biotech Corporation (NASDAQ) down 16.68%, the company has a market capitalization of $6.24 billion and a stock upside of 78.73%. For investors searching for cell therapy stocks, oncology stocks, cancer treatment stocks, biotech stocks with upside, and healthcare stocks to buy now, Legend Biotech Corporation (NASDAQ) remains a major name because it specializes in novel cell therapies for oncology and other indications.
Legend Biotech Corporation (NASDAQ) recently announced the first human proof-of-concept results for LB2501, its experimental next-generation cancer therapy, and Legend Biotech Corporation (NASDAQ) presented the data at the European Hematology Association 2026 Congress. For Legend Biotech Corporation (NASDAQ), this update matters because first human proof-of-concept data can help investors understand whether a next-generation therapy is moving from scientific theory into clinical reality. In biotech investing, especially in oncology, early human data can either strengthen confidence in a platform or raise new questions about safety, efficacy, and development risk.
Legend Biotech Corporation (NASDAQ) said LB2501 is designed for patients with B-cell non-Hodgkin lymphoma, a blood cancer affecting white blood cells. What makes Legend Biotech Corporation (NASDAQ)’s LB2501 different from existing cell therapies is the way it is designed to work. Traditional cell therapies often require removing a patient’s immune cells, engineering those cells in a laboratory, and then reinfusing them into the body. Legend Biotech Corporation (NASDAQ) is taking a different approach with LB2501 by delivering genetic instructions directly into the patient’s body through a single intravenous infusion.
Legend Biotech Corporation (NASDAQ) reported that its ongoing Phase 1 trial tested two dose levels with six patients each. At the lower dose, Legend Biotech Corporation (NASDAQ) said the results were modest. At the higher dose, however, all six patients responded, and five achieved a complete response. For Legend Biotech Corporation (NASDAQ), that higher-dose signal is the part investors will likely focus on because complete response data in blood cancer can be highly meaningful, even though the trial is still small and early. Early-stage results should always be treated carefully, but they can still shape how Wall Street views a company’s pipeline.
Legend Biotech Corporation (NASDAQ) also said no serious adverse events or treatment-related deaths were reported at the data cutoff, although about two-thirds of patients experienced cytokine release syndrome. Legend Biotech Corporation (NASDAQ) described cytokine release syndrome as an immune overreaction that is common with this class of therapy. For investors evaluating Legend Biotech Corporation (NASDAQ), safety remains central because cell therapies can be powerful, but they can also carry meaningful immune-related risks. A therapy that shows strong response rates while keeping safety manageable could become a valuable oncology asset if the results hold up in larger studies.
Legend Biotech Corporation (NASDAQ) further noted that the modified virus used to deliver the genetic instructions was no longer detected in circulation within 24 hours of infusion. Legend Biotech Corporation (NASDAQ) also said the therapy left a highly diverse, polyclonal integration pattern, which means the reprogramming appeared to happen in a broad, distributed way rather than concentrating in only specific cells. For Legend Biotech Corporation (NASDAQ), that detail gives investors another technical point to study as they judge whether LB2501 could become a differentiated next-generation cell therapy. With a $6.24 billion market capitalization, 31 hedge fund holders, and a 78.73% stock upside estimate, Legend Biotech Corporation (NASDAQ) remains one of the most promising healthcare stocks according to Wall Street analysts.
Click next to see the following stock...
